November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
What’s next for combinatorial therapy in mUC – CEC Oncology
Nov 8, 2024, 19:30

What’s next for combinatorial therapy in mUC – CEC Oncology

CEC Oncology shared a post on X:

What’s next for combinatorial therapy in mUC? Discover new possibilities in treatment with antibody-drug conjugates and take your practice to the next level.

Join Petros Grivas and Daniel Petrylak to earn free CME credit!

Book now.”

What’s next for combinatorial therapy in mUC - CEC Oncology

More posts featuring Petros Grivas and Daniel Petrylak.

Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.

Daniel Petrylak, MD, is the Director of Genitourinary Oncology and Co-Director of the Signal Transduction Program at Yale University Cancer Center. Specializing in prostate, bladder, and kidney cancers, he focuses on developing innovative drug therapies. Prior to his role at Yale, Dr. Petrylak was the Director of Genitourinary Oncology at Columbia Presbyterian Medical Center and a Professor of Medicine at Columbia University Medical Center.